UroAlerts - Prostate Cancer Weekly

September 12, 2023

Videos

Peer-to-Peer Clinical Conversations

The Intersection of Insurance with Shared Decision Making for Advanced Prostate Cancer Care - Rand Wilcox Vanden Berg

Rand Wilcox Vanden Berg

In this discussion, Ruchika Talwar and Rand Wilcox Vanden Berg delve into the intricacies of patient-physician shared decision-making for advanced prostate cancer treatment, and its intersection with insurance policies.

Lutetium-177 Therapy Yields Outstanding Response in Chemo-Naive Prostate Cancer Patient - Nasrin Ghesani

Nasrin Ghesani

Nasrin Ghesani shares a case of a 71-year-old prostate cancer patient's significant recovery with lutetium-177 therapy.

Beyond the Abstracts

Assessing the Feasibility of Utilizing Artificial Intelligence-Segmented Dominant Intraprostatic Lesion for Focal Intraprostatic Boost with External Beam Radiation Therapy - Beyond the Abstract

Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer - Beyond the Abstract

Conference Coverage

ASCO 2023: Enzalutamide, Docetaxel and Androgen Deprivation (ENZADA Trial) for Metastatic Castrate Sensitive Prostate Cancer

ASCO 2023: Early Changes of PSMA PET Signal After Initiation of Androgen Receptor Signaling Inhibitors in mCRPC: An International Multicenter Retrospective Study

ASCO 2023: Early Results from CASCARA: A Phase 2 Study of Cabazitaxel/Carboplatin plus Abiraterone in High-Volume Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.

Germline Genetic Testing After Cancer Diagnosis.

Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion.

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.

Mount Sinai Awarded $3.4 Million to Study Prostate Cancer in People With HIV

Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy.

Clinical Significance of Radical Prostatectomy in Clinical Lymph Node Metastasis in Prostate Cancer.

From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life.

Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites.

Racial/Ethnic Disparities in Prostate Cancer 5-Year Survival: The Role of Health-Care Access and Disease Severity.

Prognostic Role of Dynamic Changes in Serological Markers in Metastatic Hormone Naïve Prostate Cancer.

Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectom

Application of next-generation imaging in biochemically recurrent prostate cancer.

Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of 177Lu-PSMA I&T.

A systematic review evaluating the effectiveness of exercise training on physical condition in prostate cancer patients undergoing androgen deprivation therapy.

Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.

Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.

Relative search popularity of five advanced prostate cancer medications using Google Trends.

Molecular features of prostate cancer post-neoadjuvant therapy in the Phase 3 CALGB 90203 trial.

Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer.

The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer.

IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer.

Reirradiation salvage radiotherapy for recurrent prostate cancer after primary low-dose brachytherapy.

Image-guided radiation therapy produces lower acute and chronic gastrointestinal and genitourinary toxicity in prostate cancer patients.

Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.

Robot-assisted PSMA-radioguided surgery to assess surgical margins and nodal metastases in prostate cancer patients: report on three cases using an intraoperative PET-CT specimen imager.

Extraperitoneal robot-assisted radical prostatectomy with the Hugo™ RAS system: initial experience of a tertiary center with a high background in extraperitoneal laparoscopy surgery.

State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature.

Quality rectal hydrogel placement allows for gel-enabled dose-escalated EBRT (GEDE-EBRT) without rectal interference in prostate cancer.

JNM Publishes Consensus Statement on Patient Selection and Appropriate Use of Lu-177 PSMA-617 Radionuclide Therapy

Androgen deprivation therapy in localized prostate cancer. Current status and future trends.

Emerging role of miRNA in prostate cancer: A future era of diagnostic and therapeutics.

Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression.

Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.

Prostate cancer-multiparametric MRI and alternative approaches in intervention and therapy planning.

"TREXIT 2020": Why the Time to Abandon Transrectal Prostate Biopsy Starts Now - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
1390 Ione Pass Trail,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2023 Digital Science Press, LLC